CEO to present at ThinkEquity Conference; updates on Phase 2 glioblastoma trial and diagnostics

Shuttle Pharmaceuticals Holdings, Inc.

CEO Dr. Anatoly Dritschilo will present at ThinkEquity Conference on Oct 30, 2024 at 8:30am ET.
Presentation covers Phase 2 trial of Ropidoxuridine for glioblastoma; no new data disclosed.
Update on Shuttle Diagnostics subsidiary: predictive biomarkers for prostate cancer and PSMA ligand.
Company posted updated investor presentation on its website; one-on-one meetings available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.